Advances in protease inhibitors. Clearinghouse, P.O. Box 6003, Rockville, MD 20849-6003. 800-458-5231 ext. 5023. NLM AIDSLINE Important note: Information in this article was accurate in 1995. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Advances in protease inhibitors. Clearinghouse, P.O. Box 6003, Rockville, MD 20849-6003. 800-458-5231 ext. 5023.

PI Perspect. 1995 May;(no 16):8-9. Unique Identifier : AIDSLINE AIDS/95700459
Cheng B

Abstract: Advances in protease inhibitor clinical studies are discussed for the following inhibitors: Merck MK-639, Abbott ABT-538, Hoffman-La Roche saquinavir, and Agouron AG1343. It is noted that results from a phase II study of MK-639 are showing impressive antiviral activity with the only significant side effects being hyperbilirubinemia, and at high doses, development of kidney stones. Cross resistance started developing in long-term users of the drug. ABT-538 is also showing impressive antiviral activity in both European and U.S. phase I/II studies, and three further studies are planned, involving AZT-experienced volunteers. Currently, there are no plans to provide ABT-538 through an early access program. At higher doses than used in earlier studies, saquinavir is also showing increased antiviral activity. Doses now need to be two or three times higher than the dose being studied in earlier Phase III studies due to poor drug bioavailability. Early results from a pilot Phase II study of AG1343 are also showing clear evidence of antiviral activity with no serious adverse side effects reported. Only one dose level has been studied thus far.
Keywords: Clinical Trials, Phase I Clinical Trials, Phase II Clinical Trials, Phase III CD4 Lymphocyte Count Drug Design Human HIV Protease Inhibitors/*THERAPEUTIC USE Pyridines/THERAPEUTIC USE NEWSLETTER ARTICLEKWDclinicaltrials,phaseiclinicaltrials,phaseiiclinicaltrials,phaseiiicd4lymphocytecountdrugdesignhumanhivproteaseinhibitors/KWDtherapeuticusepyridines/therapeuticusenewsletterarticle
951230
M95C3175

Copyright © 1995 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1995. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1995. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .